Introduction to Renal Recovery in Hypoparathyroidism

Adults with chronic hypoparathyroidism often face a high risk of renal decline due to lifelong dependence on calcium and vitamin D supplements. However, new results from the PaTHway trial indicate that palopegteriparatide hypoparathyroidism treatment offers a transformative approach. This therapy successfully maintains mineral balance while simultaneously improving kidney health over a sustained two-year period.

Sustained Renal Benefits of Palopegteriparatide Hypoparathyroidism Treatment

The post hoc analysis of the Phase 3 trial evaluated 82 adults through Week 104. Notably, 93% of participants completed the open-label extension. Consequently, clinicians observed significant improvements in the estimated glomerular filtration rate (eGFR). Specifically, the mean increase in eGFR reached 8.9 mL/min/1.73m² at Week 52 and remained stable at 9.0 mL/min/1.73m² by Week 104.

Furthermore, 97% of patients achieved independence from conventional therapy. This shift is vital because high doses of oral calcium and active vitamin D often lead to hypercalciuria and renal calcification. Additionally, 82% of participants maintained normal albumin-adjusted serum calcium levels. Mean serum phosphate and calcium-phosphate product levels also stayed within healthy ranges.

In contrast to traditional management, palopegteriparatide addresses the underlying hormone deficiency directly. As a result, it reduces the need for massive oral supplementation. Consequently, this leads to lower urinary calcium excretion and preserved renal filtration over the long term.

Clinical Implications for Long-term Management

The safety profile of the drug remains favorable, with most adverse events being mild to moderate. No new safety signals emerged during the second year of the study. Therefore, these results suggest that palopegteriparatide might prevent the progressive kidney damage typically seen in this patient population. Doctors should consider these findings when managing patients who show signs of declining renal function under standard care.

Frequently Asked Questions

How does palopegteriparatide improve kidney function?

The drug replaces the missing parathyroid hormone, which helps the kidneys reabsorb calcium and excrete phosphate properly. By reducing the reliance on high-dose oral calcium, it lowers the renal load and significantly improves the eGFR.

Can patients stop taking Vitamin D supplements?

Yes, data from the PaTHway trial showed that 97% of participants became independent from conventional therapy, which specifically includes active vitamin D and high-dose elemental calcium supplementation.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Rejnmark L et al. Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial. J Bone Miner Res. 2026 May 21. doi: undefined. PMID: 42166177.

Rejnmark L, et al. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024;41(6):2500-2518.

Khan AA, et al. Standards of Care for Hypoparathyroidism in Adults: A Canadian and International Consensus. J Bone Miner Res. 2022;37:2568-2585.